Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed by JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “overweight” rating reiterated by equities researchers at JPMorgan Chase & Co. in a note issued to investors on Tuesday, Benzinga reports. They currently have a $34.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 63.78% from the stock’s previous close.

SNDX has been the subject of several other reports. Citigroup dropped their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Stifel Nicolaus increased their target price on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Scotiabank cut shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their price objective for the company from $36.00 to $23.00 in a research note on Wednesday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $41.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Syndax Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ SNDX opened at $20.76 on Tuesday. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -6.45 and a beta of 1.01. The company’s 50-day simple moving average is $22.03 and its 200-day simple moving average is $20.72. Syndax Pharmaceuticals has a 52-week low of $11.22 and a 52-week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.11. During the same quarter in the previous year, the business earned ($0.59) earnings per share. Equities research analysts anticipate that Syndax Pharmaceuticals will post -3.58 EPS for the current fiscal year.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SNDX. CWM LLC boosted its stake in Syndax Pharmaceuticals by 415.3% during the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after buying an additional 1,358 shares during the period. MeadowBrook Investment Advisors LLC purchased a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth approximately $37,000. Quadrant Capital Group LLC increased its holdings in Syndax Pharmaceuticals by 158.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after purchasing an additional 1,496 shares during the last quarter. Annandale Capital LLC acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at approximately $67,000. Finally, Signaturefd LLC raised its position in Syndax Pharmaceuticals by 2,874.6% in the fourth quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock valued at $81,000 after purchasing an additional 3,622 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).